PT-141 (Bremelanotide)
Sexual health · By Preptide Pro editorial team · Last updated
PT-141 (Bremelanotide) is a sexual health peptide, and it has an FDA-approved product. A melanocortin receptor agonist. Approved by the FDA for acquired generalized hypoactive sexual desire disorder in premenopausal women.
FDA-approved (see products)Chemistry (PubChem)
| PubChem CID | 9941379 |
|---|---|
| CAS number | 189691-06-3 |
| Molecular formula | C50H68N14O10 |
| Molecular weight | 1025.2 g/mol |
| Other names | Bremelanotide, Bremelanotida, PT-141 FREE BASE, PT 141, Bremelanotidum, RefChem:58355, DTXCID701323799, PT-141 |
Is PT-141 (Bremelanotide) FDA-approved?
| Brand | Application | Status | Sponsor |
|---|---|---|---|
| VYLEESI (AUTOINJECTOR) | NDA210557 | Prescription | COSETTE |
How much research is there on PT-141 (Bremelanotide)?
PubMed lists 110 records for “bremelanotide”, of which 15 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. | Sex Med Rev | 2026 Sep 30 |
| Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling. | Anal Methods | 2026 Aug 20 |
| Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors. | J Med Chem | 2026 Aug 13 |
| Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer. | J Minim Invasive Gynecol | 2026 Jul |
| Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov. | Front Med (Lausanne) | 2026 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.